Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
Trial record 1 of 327154 for:    ALL
Previous Study | Return to List | Next Study

A Phase II Study of Cabozantinib (XL 184) Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04230954
Recruitment Status : Not yet recruiting
First Posted : January 15, 2020
Last Update Posted : January 15, 2020
Sponsor:
Collaborator:
Exelixis
Information provided by (Responsible Party):
University of South Alabama

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : June 28, 2021
Estimated Study Completion Date : January 28, 2022